Treatment | Recommendations |
---|---|
Vital distress | - Immediately and as soon as possible: |
- Administer icatibant (Firazyr®): 30 mg subcutaneously or | |
- plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously | |
- Switch the call to the local SAMU to send French EMS | |
- Gain control of upper airway | |
Severe attacks | - Immediately and as soon as possible: |
Laryngeal | - Administer icatibant (Firazyr®): 30 mg subcutaneously or |
Facial | - plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously |
Abdominal | - If treatments are unavailable at home, switch the call to the local SAMU to send an ambulance headed towards a hospital with specific treatments available or being able to get them by French EMS |
- Gain control of upper airway | |
Non-severe attacks (members, genitals) | - Tranexamic acid: 1 g/6 h except for patients who are breastfeeding or have thromboembolic pathology |
Surveillance in all cases | Monitoring by phone 30 min, 1 h, 4 h, 12 h and 24 h after the beginning of the attack |
Advice to call back SOS-HAE call centre in case of secondary worsening |